Evidence map›Paper›PMID 35260705›Full record

ArticleScientific reports2022

An animal model of limitation of gut colonization by carbapenemase-producing Klebsiella pneumoniae using rifaximin.

Eleni Xenofontos, Georgios Renieris, Maria Kalogridi, Dionyssia-Eirini Droggiti, Kalliopi Synodinou, Georgia Damoraki, Panagiotis Koufargyris, Labros Sabracos, Evangelos J Giamarellos-Bourboulis

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Hypermucoviscous Carbapenem-ResistantInternational journal of molecular sciences · 2023
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Eleni Xenofontos4th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece.
Georgios Renieris4th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece.
Maria Kalogridi4th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece.
Dionyssia-Eirini Droggiti4th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece.
Kalliopi Synodinou4th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece.
Georgia Damoraki4th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece.
Panagiotis Koufargyris4th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece.
Labros Sabracos4th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece.
Evangelos J Giamarellos-Bourboulis4th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece. egiamarel@med.uoa.gr.
National and Kapodistrian University of Athens · GRUniversity General Hospital Attikon · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Current knowledge suggests that infection by carbapenem-resistant enterobacteria is preceded by gut colonization. It is hypothesized that colonization is eradicated by non-absorbable antibiotics like rifaximin. We investigated the effect of rifaximin against carbapenem-resistant Klebsiella pneumoniae (CRKP) in vitro and in a mouse model. We studied the in vitro efficacy of rifaximin against 257 CRKP clinical isolates, 188 KPC producers and 69 OXA-48 producers, by minimum inhibitory concentration and time-kill assays. We then developed a model of gut colonization by feeding 30 C57Bl6 mice with 10

Indexed as

Carbapenem-Resistant EnterobacteriaceaeKlebsiella InfectionsAmpicillinAnimalsAnti-Bacterial AgentsBacterial Proteinsbeta-LactamasesCarbapenemsDisease Models, AnimalKlebsiella pneumoniaeMiceMice, Inbred C57BLMicrobial Sensitivity TestsRifaximinAmpicillinAnti-Bacterial AgentsBacterial Proteinsbeta-LactamasescarbapenemaseCarbapenemsRifaximin

Identifiers

PMID35260705
PMCPMC8904601
OpenAlexW4220870627

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.